Leerink Partnrs Research Analysts Lift Earnings Estimates for 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Free Report) – Equities research analysts at Leerink Partnrs raised their Q4 2023 earnings per share (EPS) estimates for 4D Molecular Therapeutics in a research note issued to investors on Wednesday, February 7th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings of ($0.39) per […]

Related Keywords

Canada ,United States ,American ,Robert Young Kim ,David Kirn ,Leerink Partnrs ,Pricet Rowe Associates Inc ,American International Group Inc ,Royal Bank ,Goldman Sachs Group ,D Molecular Therapeutics Inc ,Cantor Fitzgerald ,Lazard Asset Management ,Manufacturers Life Insurance Company ,Nasdaq ,Daiwa Securities Group Inc ,Molecular Therapeutics ,Free Report ,Molecular Therapeutic ,Get Free Report ,Asset Management ,International Group ,Daiwa Securities Group ,Securities Group ,Molecular Therapeutics Daily ,4d Molecular Therapeutics ,Nasdaq Fdmt ,Fdmt ,Medical ,Earnings Estimates ,